UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 84

of 'Induction therapy for acute myeloid leukemia in younger adults'

84
TI
Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.
AU
Jentsch-Ullrich K, Pelz AF, Braun H, Koenigsmann M, Mohren M, Wieacker P, Franke A
SO
Haematologica. 2004;89(5):ECR15. Epub 2004 May 1.
 
Philadelphia-chromosome (Ph)-positive acute myeloid leukemia (AML) is rare and prognosis is poor with a median survival of six to seven months only. We report on a patient with Ph-positive AML (FAB M2, major BCR/ABL1 mRNA transcript, b2a2), who is in sustained complete cytogenetic and molecular remission for 15 months. Cytarabine-based chemotherapy was discontinued after two courses due to infectious complications. Since the b2a2 transcript was still detectable, imatinib was started with quantitative RT-PCR monitoring. This result is promising and worth further evaluation to establish the role of imatinib in patients with Ph-positive AML.
AD
University Hospital Magdeburg, Division of Hematology/Oncology, Leipziger Str.44, 39120 Magdeburg, Germany. Kathleen.Jentsch-Ullrich@Medizin.Uni-Magdeburg.de
PMID